Benjamin Mulkey
Roanoke, VANPI 1124522115
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (39.8%), food and beverage and grants — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Medtronic at 27.6% of the total. 2025 is the largest year on record at $22,971, more than ten times the $178 reported in 2021.
Across 212 payments — averaging $169.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$10K
- Abbott$9K
- Biotronik Inc.$6K
- Biosense Webster, Inc.$5K
- Boston Scientific$4K
- Medical Device Business Services, Inc.$486
- plus $1K from 14 others
What the payments were for
- Grants$10,00028%
- Travel & lodging$14,31140%
- Food & beverage$10,83830%
- Education$8082%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 41 | $9,931 |
| Abbott | 37 | $8,916 |
| Biotronik Inc. | 40 | $5,842 |
| Biosense Webster, Inc. | 38 | $4,996 |
| Boston Scientific | 25 | $4,376 |
| Medical Device Business Services, Inc. | 1 | $486 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $394 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $175 |
| Abiomed | 2 | $161 |
| Cardiovascular Systems Inc. | 1 | $126 |
| Pfizer | 3 | $126 |
| Boehringer Ingelheim | 1 | $112 |
| E.r. Squibb & Sons, L.L.C. | 1 | $74 |
| Teleflex LLC | 1 | $66 |
| Stryker | 2 | $44 |
| Philips North America LLC | 1 | $44 |
| Recor Medical Inc | 1 | $25 |
| Johnson & Johnson | 1 | $22 |
| Inari Medical, Inc. | 1 | $21 |
| Bridgebio Pharma, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$4,631
- TACTICATH$2,500
- ASSURITY$2,500
- ENSITE$2,163
- VersaCross Access Solution$1,599
- ENSITE PRECISION$574
- Micra$547
- ONYX FRONTIER$372
- ACCOLADE SR$258
- COBALT DR MRI SURESCAN$230
- PulseSelect$173
- LINQ II$142
- AZURE XT DR MRI SURESCAN$127
- Diamondback Coronary$126
- AURORA EV-ICD MRI SURESCAN$120
- WATCHMAN FLX$115
- JARDIANCE$112
- Impella$103
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $58,658 |
| Rosuvastatin Calcium | 62 | $986 |
| Metoprolol Succinate | 38 | $339 |
| Ezetimibe | 21 | $281 |
| Atorvastatin Calcium | 42 | $274 |
| Pantoprazole Sodium | 11 | $262 |
| Amiodarone Hcl | 15 | $228 |
| Metoprolol Tartrate | 25 | $148 |
| Carvedilol | 12 | $121 |
| Losartan Potassium | 15 | $77 |
| Hydrochlorothiazide | 16 | $30 |
| Klor-Con M20Potassium Chloride | 11 | $22 |
| Amlodipine Besylate | 13 | $5 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $126 | $58,65856 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Virginiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.